Aquestive Therapeutics (NASDAQ:AQST) Announces Earnings Results, Misses Estimates By $0.01 EPS

Aquestive Therapeutics (NASDAQ:AQST) released its earnings results on Monday. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Zacks reports. The business had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same quarter last year, the firm posted ($0.03) EPS.

Aquestive Therapeutics Price Performance

Shares of AQST stock traded up $0.32 during mid-day trading on Wednesday, hitting $5.07. 1,948,168 shares of the stock traded hands, compared to its average volume of 1,755,199. The stock’s fifty day moving average is $4.90 and its two-hundred day moving average is $3.82. Aquestive Therapeutics has a 52-week low of $1.55 and a 52-week high of $6.23. The stock has a market cap of $461.67 million, a P/E ratio of -11.00 and a beta of 2.82.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on AQST shares. Leerink Partners raised their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday. Finally, JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $8.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.